Results 31 to 40 of about 7,987 (192)

DataSheet_1_Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma.docx

, 2021
BackgroundPrimary retroperitoneal liposarcomas (RLPSs) are rare heterogeneous tumors for which there are few effective therapies. Certain anti-angiogenic tyrosine kinase inhibitors have demonstrated efficacy against various solid tumors. The aims of this
Ang Lv (413575), Zhen Wang (72451), Lixuan Cui (11722076), Min Zhao (66793), Jianhui Wu (385334), Chunyi Hao (413578), Faqiang Liu (5793560), Xiuyun Tian (185166), Liang Yan (494300), Xiaoya Guan (413577), Bin Dong (147019), Daoning Liu (11722079)   +11 more
core   +1 more source

Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro

Chinese Journal of Lung Cancer, 2020
Background and objective Lung cancer is the most common malignancy world-wide. Small cell lung cancer is the deadliest subtype of lung cancer, which features such as rapid growth, early metastasis, and high vascularization.
Chao LIU, Hongbing ZHANG, Yongwen LI, Zihe ZHANG, Ruifeng SHI, Songlin XU, Guangsheng ZHU, Pan WANG, Hongyu LIU, Jun CHEN   +9 more
doaj   +1 more source

In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation

Cancer Cell International, 2023
Background Apatinib (YN968D1) is the first small-molecule-targeting drug with anti-tumor activity created in China for the treatment of advanced gastric cancer (GC) and hepatocellular carcinoma (HCC).
Jiani Chen, Jingwen Zhai, Mingming Li, Shiyi Liu, Xiaobin Gong, Hongyu Yu, Hua Wei, Wansheng Chen   +7 more
doaj   +1 more source

Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer

Cell Death and Disease, 2022
The efficacy of apatinib has been confirmed in the treatment of solid tumors, including non-small-cell lung cancer (NSCLC). However, the direct functional mechanisms of tumor lethality mediated by apatinib and the precise mechanisms of drug resistance ...
Xiaoshu Zhou, Rui Zhou, Xinrui Rao, Jiaxin Hong, Qianwen Li, Xiaohua Jie, Jian Wang, Yingzhuo Xu, Kuikui Zhu, Zhenyu Li, Gang Wu   +10 more
doaj   +1 more source

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Frontiers in Oncology, 2020
Background: Apatinib is a powerful inhibitor of vascular endothelial growth factor receptor-2. This study was aimed to investigate whether apatinib could improve the efficacy of transarterial chemoembolization (TACE) in patients with advanced ...
Xuefeng Kan, Xuefeng Kan, Bin Liang, Bin Liang, Guofeng Zhou, Guofeng Zhou, Bin Xiong, Bin Xiong, Feng Pan, Feng Pan, Yanqiao Ren, Yanqiao Ren, Yanyan Cao, Yanyan Cao, Jihua Wang, Jihua Wang, Fan Yang, Fan Yang, Chuansheng Zheng, Chuansheng Zheng   +19 more
doaj   +1 more source

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats

Frontiers in Pharmacology, 2022
Purpose: The “radiotherapy-pharmacokinetic” (“RT-PK”) phenomenon refers to the fact that radiation can significantly alter the pharmacokinetic behavior of a drug. At present, it is not clear whether there is an “RT-PK” phenomenon that can affect apatinib
Shi-Qi Dong, Fan Yang, Dong-Xu Zhang, Ling-Mei Wang, Jian-Feng Liu, Ai-Jie Zhang, Hui-Rong Fan   +6 more
doaj   +1 more source

Population Pharmacokinetics and Pharmacogenetics of Apatinib in Adult Cancer Patients

, 2023
OBJECTIVE: Apatinib is widely used in Chinese cancer patients. As the in vivo drug disposition of apatinib has large individual differences, adverse events are prone to occur.
Min Kan, Zhang, Ye-Hui, Ya Li, Xiao‐Lin Liu, Liu, Xiao-Lin, Ye, Pan-Pan, Li, Yan, Pan‐Pan Ye, Fu‐Rong Zhao, Zi‐Xuan Guo, Chen, Ke-Guang, Xin‐Mei Yang, Guo, Zi-Xuan, Shi, Jin-Yi, Yan Li, Zhao, Wei, Kan, Min, Zhao, Fu-Rong, Lin‐Lin Song, Yang, Xin-Mei, Song, Lin-Lin, van den Anker, John, Ye‐Hui Zhang, Li, Qian, Hong‐Ying Liu, Liu, Hong-Ying, Wei Zhao, Li, Ya, Jin‐Yi Shi, Qian Li, John van den Anker, Ke‐Guang Chen   +31 more
core   +1 more source

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in esophageal squamous cell carcinoma

Cell & Bioscience, 2021
Background Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, has been approved for the treatment of metastatic gastric cancer and other tumors.
Yu-Ming Wang, Xin Xu, Jian Tang, Zhi-Yong Sun, Yu-Jie Fu, Xiao-Jing Zhao, Xiu-Mei Ma, Qing Ye   +7 more
doaj   +1 more source

Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer [PDF]

, 2021
BackgroundApatinib is a new generation of small molecule tyrosine kinase inhibitor, which can highly selectively inhibit phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR-2).
Kong, Dejiu, Li, Yuanpei, Yuan, Xiang, Zhang, Yifan, Liang, Gaofeng, Wang, Xinshuai, Deng, Shuzhen, Hu, Xiaochen, Chen, Jing, Wang, Chaokun   +9 more
core   +1 more source

Reversal Effect of Apatinib on P-gp-mediated Multidrug Resistance of Human Breast Cancer and Its Mechanisms

Zhongliu Fangzhi Yanjiu, 2018
Objective To investigate the reversal effect of apatinib on the multidrug resistance of human breast cancer and the underlying mechanisms. Methods MCF-7 and MCF-7/ADR cells were treated with different concentrations of apatinib for 48h.
ZHANG Shengcun, MA Min, XU Lili
doaj   +1 more source